A question that is frequently asked from investors is if medicinal Cannabis products can be distributed through private pharmacies in Greece.
As of June 27th 2019, the Greek state and the National Organization of Medicine (EOF), decided to transfer medicinal cannabis products with THC >0.2%, to Table C from Table B according to the recent decision by the Greek State.
This implies that medicinal Cannabis products can be also available through private pharmacies in Greece while products listed in table B are only available through the State Monopoly (state hospitals).
This gives a real boost in medical cannabis investments since the Greek market is now opened to absorb relevant products. It is necessary to note that the National Organization of Medicine (EOF) is a full member of European Medicines Agency (E.M.A.) implying that this decision will possibly trigger similar ones to be taken in other countries too, if not already taken.
To give the overall picture of medicinal products Tables for cannabis products, the following taxonomy applies:
Table A: are included substances with negative effects more than the positive ones and thus they can be only used for R &D purposes.
Table B: are included medicines with positive effects (at least more than negatives ones) and therefore they can be only distributed through the Greek State Monopoly (state hospitals).
Medicinal Cannabis products can be distributed through private pharmacies in Greece is one of the reasons why Greece is a favorable country for medical cannabis production facilities.
Tables C & D: are included medicines that can be also distributed through the private pharmacies throughout Greece.
It is worth stating that until few years before, cannabis and its derivatives were widely restricted under the assumption that they had no medical value and carried a substantial risk for people health. This picture is changing fast, since medicinal cannabis products can now be prescribed for pharmaceutical use in many countries. This creates an emerging market and significant new opportunities for new medical treatments.
Relevant reference of this decision by the Greek State included in the below link: